Physician profile
Peter Stathopoulos
NPI 1265405161
$2,871.62
in general payments reported to CMS, 2019-2025
33 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $139 · 2021: $727 · 2022: $355 · 2023: $350 · 2024: $558 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,149 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.18 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $522.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $302.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $271.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $220.59 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.49 | 2019-2025 | Jardiance |
| Medtronic, INC. | $174.88 | 2021 | |
| Pfizer INC. | $174.44 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $125.00 | 2022 | |
| Abbvie INC. | $120.29 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.57 | 2019-2024 | Cycloset |
| Novo Nordisk INC | $66.79 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $66.79 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $52.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.57 | 2023-2024 | Aralast |
| Esperion Therapeutics, INC. | $43.68 | 2020-2024 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $38.78 | 2022-2023 | Accrufer |
| Astellas Pharma US INC | $33.51 | 2023 | Veozah, Myrbetriq |
| Allergan, INC. | $28.21 | 2020 | |
| Mallinckrodt Hospital Products INC. | $22.30 | 2022 | |
| Gilead Sciences, INC. | $20.45 | 2024 | |
| Genentech USA, INC. | $19.97 | 2019 | |
| Dexcom, INC. | $19.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.43 | 2023 | Spravato |
| Philips North America LLC | $18.38 | 2020 | |
| Hologic Sales and Service, LLC | $18.35 | 2022 | |
| Inspire Medical Systems, INC. | $16.97 | 2025 | Inspire |
| Amarin Pharma, INC. | $16.68 | 2020 | |
| Renalytix Ai, INC. | $16.44 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| E.R. Squibb & Sons, L.L.C. | $15.08 | 2022 | |
| Dynavax Technologies Corporation | $14.51 | 2023 | Heplisav-B |
| Exact Sciences Corporation | $14.14 | 2023 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $11.57 | 2019 | |
| Boston Scientific Corporation | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Stathopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.